122 related articles for article (PubMed ID: 38916601)
1. Vaccine Effectiveness against SARS-CoV-2 among Household Contacts during Omicron BA.2-Dominant Period, Japan.
Ogata T; Tanaka H; Kon A; Sakaibori N; Tanaka E
Emerg Infect Dis; 2024 Jul; 30(7):1430-1433. PubMed ID: 38916601
[TBL] [Abstract][Full Text] [Related]
2. How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022.
Althaus T; Overton CE; Devaux I; House T; Lapouze A; Troel A; Vanzo B; Laroche M; Bordero A; Jorgensen P; Pebody R; Voiglio EJ
BMC Med; 2024 Jun; 22(1):227. PubMed ID: 38840159
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China.
Liao Y; Su J; Zhao J; Qin Z; Zhang Z; Gao W; Wan J; Liao Y; Zou X; He X
Front Immunol; 2024; 15():1359380. PubMed ID: 38881892
[TBL] [Abstract][Full Text] [Related]
4. Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China.
He X; Liao Y; Liang Y; Yu J; Gao W; Wan J; Liao Y; Su J; Zou X; Tang S
Front Immunol; 2023; 14():1290279. PubMed ID: 38259438
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of BNT162b2 Vaccine Against Symptomatic SARS-CoV-2 Infection in Children Aged 5-11 Years in Japan During Omicron Variant Predominate Periods.
Hara M; Ohta Y; Fusazaki N; Hirota Y
J Epidemiol; 2024 May; 34(5):205-210. PubMed ID: 37460294
[TBL] [Abstract][Full Text] [Related]
6. Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China.
Wang K; Guo Z; Zeng T; Sun S; Lu Y; Wang J; Li S; Luan Z; Li H; Zhang J; Wang Y; Lu Y; Zhao S
JAMA Netw Open; 2023 Mar; 6(3):e235755. PubMed ID: 36995713
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain.
López-Muñoz I; Torrella A; Pérez-Quílez O; Castillo-Zuza A; Martró E; Bordoy AE; Saludes V; Blanco I; Soldevila L; Estrada O; Valerio L; Roure S; Vallès X
Emerg Infect Dis; 2022 Oct; 28(10):1999-2008. PubMed ID: 36037811
[TBL] [Abstract][Full Text] [Related]
8. Increased Secondary Attack Rates among the Household Contacts of Patients with the Omicron Variant of the Coronavirus Disease 2019 in Japan.
Ogata T; Tanaka H; Tanaka E; Osaki N; Noguchi E; Osaki Y; Tono A; Wada K
Int J Environ Res Public Health; 2022 Jun; 19(13):. PubMed ID: 35805724
[TBL] [Abstract][Full Text] [Related]
9. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Maeda H; Saito N; Igarashi A; Ishida M; Terada M; Ito T; Ikeda H; Kamura H; Motohashi I; Kimura Y; Komino M; Arai H; Kuwamitsu O; Akuzawa N; Sando E; Morikawa T; Imura H; Inoue H; Hayakawa T; Teshigahara O; Ohara Y; Suzuki M; Morimoto K
Expert Rev Vaccines; 2023; 22(1):288-298. PubMed ID: 36883371
[TBL] [Abstract][Full Text] [Related]
11. Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022.
Hoeve CE; de Gier B; Huiberts AJ; de Melker HE; Hahné SJM; van den Hof S; Knol MJ
J Infect Dis; 2023 Aug; 228(4):431-438. PubMed ID: 37093964
[TBL] [Abstract][Full Text] [Related]
12. Household Secondary Attack Rates of SARS-CoV-2 Omicron Variant, South Korea, February 2022.
Lim DS; Choe YJ; Man Kim Y; Lee SE; Jang EJ; Kim J; Park YJ
Emerg Infect Dis; 2022 Aug; 28(8):1731-1734. PubMed ID: 35798007
[TBL] [Abstract][Full Text] [Related]
13. Effect of COVID-19 vaccination on household transmission of SARS-CoV-2 in the Omicron era: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
Maeda M; Murata F; Fukuda H
Int J Infect Dis; 2023 Sep; 134():200-206. PubMed ID: 37356650
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
[TBL] [Abstract][Full Text] [Related]
15. Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.
Braeye T; Catteau L; Brondeel R; van Loenhout JAF; Proesmans K; Cornelissen L; Van Oyen H; Stouten V; Hubin P; Billuart M; Djiena A; Mahieu R; Hammami N; Van Cauteren D; Wyndham-Thomas C
Vaccine; 2023 May; 41(20):3292-3300. PubMed ID: 37085456
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Maeda H; Saito N; Igarashi A; Ishida M; Terada M; Masuda S; Osawa R; Hosokawa N; Nakashima K; Kamura H; Imura H; Inoue H; Matsuzaka S; Sugimoto Y; Kuwamitsu O; Motohashi I; Morikawa T; Oda R; Hoshina Y; Matono T; Teshigahara O; Sando E; Asami S; Kudo S; Akizuki N; Muto Y; Hayakawa T; Kishaba T; Ohara Y; Kubo Y; Suzuki M; Morimoto K
Expert Rev Vaccines; 2024; 23(1):213-225. PubMed ID: 38288980
[TBL] [Abstract][Full Text] [Related]
17. Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis.
Madewell ZJ; Yang Y; Longini IM; Halloran ME; Dean NE
JAMA Netw Open; 2022 Apr; 5(4):e229317. PubMed ID: 35482308
[TBL] [Abstract][Full Text] [Related]
18. Impact of SARS-CoV-2 vaccines on Covid-19 incidence and mortality in the United States.
Fang F; Clemens JD; Zhang ZF; Brewer TF
PLoS One; 2024; 19(4):e0301830. PubMed ID: 38656933
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.
Ng OT; Marimuthu K; Koh V; Pang J; Linn KZ; Sun J; De Wang L; Chia WN; Tiu C; Chan M; Ling LM; Vasoo S; Abdad MY; Chia PY; Lee TH; Lin RJ; Sadarangani SP; Chen MI; Said Z; Kurupatham L; Pung R; Wang LF; Cook AR; Leo YS; Lee VJ
Lancet Infect Dis; 2021 Mar; 21(3):333-343. PubMed ID: 33152271
[TBL] [Abstract][Full Text] [Related]
20. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
